Intravenous to oral transition of antibiotics for gram-negative bloodstream infection at a University hospital in Thailand: Clinical outcomes and predictors of treatment failure

Titawadee Pradubkham¹, Gompol Suwanpimolkul², Alan Edward Gross³, Chotirat Nakaranurack⁴*

¹ College of Pharmacotherapy Thailand, Nontaburi, Thailand, ² Faculty of Medicine, Division of Infectious Diseases, Department of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand, ³ Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, United States of America, ⁴ Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand

* chotirat.n@pharm.chula.ac.th

Abstract

Background

Limited studies evaluate the outcome of intravenous antibiotics to oral transition in Gram-negative bloodstream infection (GN-BSI), particularly GN-BSI originating outside the urinary tract. This study aimed to evaluate treatment success in patients with GN-BSI treated with either intravenous therapy or intravenous to oral transition and to identify factors associated with treatment failure in those undergoing intravenous to oral transition.

Methods

A retrospective cohort study was conducted at King Chulalongkorn Memorial Hospital, Thailand. Patients were included if they were ≥18 years of age, hospitalized in general medical wards with GN-BSI between August 1, 2015, to July 31, 2020, received intravenous antibiotic agents and had a functioning gastrointestinal tract.

Results

Of 955 patients, 545 (57.1%) were in the intravenous to oral transition group. The urinary tract was the most common source of infection (38.8%). Ciprofloxacin was the most prescribed oral antibiotic (53%). Treatment success occurred in 94.3% in the intravenous antibiotic to oral transition group. There was no significant difference in treatment success between the two groups (P = 0.790) with a concordant result after using propensity score matching (P = 0.223). Independent predictors of treatment failure in the intravenous to oral transition group included metastatic solid cancer (aOR = 4.355), HIV infection with CD4 < 200 cells/mm³ (aOR = 8.452), qSOFA score ≥ 2 (aOR = 2.545), multidrug-resistant infection (aOR = 2.849), and respiratory tract infection (aOR = 8.447). Hospital length of stay in the intravenous to oral transition group was shorter than in the intravenous group (P < 0.001).
Conclusions

Intravenous to oral transition may be a practical approach in GN-BSI. Patients with Gram-negative bacteremia who have HIV infection with CD4 < 200 cells/mm³, multidrug-resistant infections, and respiratory tract sources of infection may not be ideal candidates for this approach. Future research is needed from a randomized controlled trial.

Introduction

Bloodstream infections (BSI) are a significant cause of morbidity and mortality in hospitalized patients [1]. The incidence of Gram-negative bloodstream infection (GN-BSI) is increasing globally, and remains a public health concern with an associated mortality of 12–25% [2–4]. Malignancy, liver cirrhosis, non-urinary tract infection, and higher Pitt bacteremia scores have been associated with higher mortality in patients with BSI [5]. Although historically GN-BSIs have been treated primarily with intravenous (IV) antibiotics, limited recent data suggest a transition from IV to oral antibiotics may be effective [6–8]. Multidrug-resistant Gram-negatives are a major public health threat around the world, especially in patients with severe infections such as BSIs. Prolonged hospitalization is associated with hospital-onset GN-BSIs and resistant pathogens [9]. Third-generation cephalosporin-resistant Enterobacteriales are the main problem in southeast Asia, with an increasing trend for carbapenem-resistant Enterobacteriales [10]. Data from National Antimicrobial Resistant Surveillance Center, Thailand (NARST) showed an increasing number of patients with carbapenem-resistant Enterobacteriales, especially Klebsiella pneumoniae, during the past ten years in Thailand [11]. Antibiotic stewardship programs (ASP) can help mitigate the threat of resistant Gram negatives through systematically optimizing the use of antibiotics and have been associated with improving patient outcomes, reducing antibiotic resistance, and decreasing healthcare costs. IV to oral transition is one ASP strategy [12]. The advantages of oral antibiotics include decreasing the risk of line complications, treatment cost, and length of hospital stay (LOS) [13–16]. However, there are only limited data evaluating the clinical outcomes and factors associated with treatment failure for IV to oral transitions in GN-BSI, especially in Thai patients. This study aimed to evaluate treatment success in patients with GN-BSI treated with either IV therapy or IV to oral transition and identify predictors of treatment failure in those undergoing IV to oral transition.

Materials and methods

Study design, setting, and participants

A retrospective cohort study was conducted at King Chulalongkorn Memorial Hospital, a 1,479-bed tertiary referral and teaching hospital in Bangkok, Thailand. The patient inclusion criteria were as follows: (1) ≥18 years of age with GN-BSI who received inpatient care within the general medical wards from August 1, 2015, to July 31, 2020. (2) Received IV antibiotic agents. (3) Intact and functioning gastrointestinal tract, defined as the absence of the following conditions: malabsorption syndrome, short bowel syndrome, severe gastroparesis, ileus, vomiting, and continuous nasogastric suction. And (4) Available active oral antibiotics options based on susceptibilities. All patients were followed until hospital discharge. Patients were excluded if they met the following criteria: (1) Hospitalization less than 24 hours. (2) Death within 24 hours of admission. (3) Chronic infection or need for prolonged use of antibiotics.
e.g., patients infected with brain abscess, septic arthritis, osteomyelitis, or infective endocarditis. (4) Uncontrolled sources of infection. (5) Patients who refused treatment or patients receiving palliative care only. (6) Patients with unavailable data in the medical record. And (7) Loss to follow up on day 30 after discharge. Patients in the IV group must have received IV antibiotics for their entire treatment duration.

The data retrieved from the paper medical records and electronic database (ePHIS) included baseline characteristics, source of infection, microorganisms, treatment, and treatment outcome. For bacterial identification, a blood sample was inoculated into an aerobic bottle of blood culture broth (BD BACTEC) and incubated at 35˚C for five days. Antibiotic susceptibility testing was performed by disk diffusion and Vitek 2 XL system in accordance with the Clinical and Laboratory Standards Institute [17]. The Institutional Review Board of the Faculty of Medicine at Chulalongkorn University approved the study and waived the need for informed consent (IRB No.744/63). All data were fully anonymized before we accessed them.

Definitions
GN-BSI was defined as a laboratory-confirmed positive blood culture with Gram-negative bacteria. The source of BSI was categorized as either primary or secondary. Secondary BSI was attributed to a body site-specific source, e.g., urinary tract, intra-abdominal tract, etc. If the BSI source could not be assigned to a specific body site despite diagnostic workup, it was classified as a primary BSI [18]. Infections identified from blood cultures taken >48 hours after admission were categorized as hospital-acquired infections, and those taken ≤48 hours after admission were categorized as community-acquired infections [19]. Sepsis and septic shock were defined according to the Third International Consensus Definition for Sepsis and Septic Shock (Sepsis 3) [20]. The Charlson comorbidity index was defined as previously described [21]. The severity of GN-BSI on day 1 of diagnosis was graded according to the Pitt bacteremia score [22–24]. Multidrug-resistant organisms were defined as resistant to at least one antibiotic from three or more classes [25]. Patients who met the following criteria on day 1 of the GN-BSI diagnosis were identified as immunocompromised: Human Immunodeficiency Virus (HIV) infection with a CD4 cell count of <200 cells/mm³, severe neutropenia (absolute neutrophil count; ANC of <500/mm³), active immunomodulatory therapy or at least 20 mg of prednisone daily or equivalent for 14 days or longer, chemotherapy within six months, or history of solid organ or hematopoietic stem cell transplant. Time to appropriate antibiotic therapy was defined as the time from identifying microorganisms to receiving antibiotics active against the microorganisms. The bioavailability of oral antibiotic agents was classified as follows: high bioavailability (>90%) included cephalexin, doxycycline, levofloxacin, moxifloxacin, and ofloxacin. Moderate bioavailability (60–90%) included ampicillin, amoxicillin, amoxicillin/clavulanic acid, ciprofloxacin, and trimethoprim/sulfamethoxazole. Low bioavailability (<60%) included ampicillin/sulbactam, cefdinir, cefditoren, cefuroxime, cefixime, and norfloxacin [26,27]. The type of IV to oral antibiotic transition was classified into three types as sequential, switch, and step-down therapy [26]. Sequential was defined as replacing an IV medication with its oral counterpart of the same compound. Switch therapy was defined as transitioning an IV medication with its oral counterpart of the same class and having the same potency level but not the same compound. Step-down therapy was defined as transitioning an IV medication with an oral agent in the spectrum of activity that may not be precisely the same. Patients were classified as having treatment success if they were afebrile (body temperature <37.8˚C) with a white blood cell count (WBC) of <11,000 cells/mm³ after 72 hours of active antibiotic treatment and did not meet any of the treatment failure criteria. Treatment
failure was a composite outcome including in-hospital mortality, relapse of BSI, and transition back from oral to IV medication. Relapse was defined as positive blood culture for the same Gram-negative microorganism within 30 days after treatment completion. Persistence of GN-BSI was defined as patients with positive blood culture for the same Gram-negative microorganism after 72 hours of active antibiotic treatment by in vitro susceptibility. Loss to follow-up on day 30 was defined as patients who didn’t return to follow up at our hospital’s clinic or receive inpatient care at our hospital on day 30 after hospital discharge.

**Statistical analysis**

Means ± standard deviations (SD), medians with interquartile ranges (IQRs), and frequencies with percentages were used to describe baseline characteristics, infection source, microorganisms, type and bioavailability of oral antibiotic agents, and type of IV to oral antibiotic transitions. The Chi-square test or Fisher’s exact test was used for categorical variables. The Student t-test or the Wilcoxon rank-sum test was used for continuous data.

A logistic regression model was developed to identify factors associated with treatment failure in the overall patient population, as well as patients in the IV group and IV to oral antibiotic agents transition group. Odds ratio (ORs) and associated 95% confidence intervals (95% CI) were calculated. Variables with a \( P \)-value of \( \leq 0.1 \) in the univariate analyses were included in multivariate analysis, using backward LR selection in the final model. Variables with \( P \)-values of \(< 0.05 \) in the multivariate analysis were considered statistically significant.

Propensity scores were calculated using a logistic regression model to balance baseline characteristics of patients in the IV group and IV to oral transition group. Covariates included in the model were preexisting medical conditions (each included separately: immunologic or rheumatologic disease, end-stage renal disease), individual immunocompromising conditions, quick Sepsis-related Organ Failure Assessment (quick SOFA) \( \geq 2 \) on day 1 of BSI, septic shock on day 1 of BSI, ICU admission on day 1 of BSI, on mechanical ventilator on day 1 of BSI, acute kidney injury on day 1 of BSI, multidrug-resistant (MDR) pathogens, and hospital-acquired BSI. One-to-one matching without replacement and propensity variable match tolerance of 0.01 was used.

All analyses were performed using Statistical Package for the Social Science (SPSS) software for Windows, Version 22.0.

**Results**

One thousand seventeen hospitalized patients with GN-BSI met the inclusion criteria. Sixty-two patients (6.1%) were lost to follow-up on day 30 after discharge (41 patients (9.1%) were in the IV group and 21 patients (3.7%) were in the IV to oral transition group). A total of 955 patients were included in the cohort study, 410 patients (42.9%) were in the IV group, and 545 patients (57.1%) were in the IV to oral transition group (Fig 1).

Patients’ baseline characteristics are summarized in Table 1. The cohort’s median age was 71 years (IQR 60–81 years), and 547 patients (57.3%) were female. There was a higher proportion of immunocompromised hosts in the IV group than in the IV to oral transition group (32.4% versus 23.1%; \( P = 0.001 \)). Patients in the IV group were more likely than the IV to oral transition group to be severely ill at the onset of BSI with a greater proportion having septic shock (21% versus 15.8%; \( P = 0.039 \)), mechanical ventilation (18.5% versus 8.6%; \( P < 0.001 \)), qSOFA scores of \( \geq 2 \) (37.6% versus 27.3%; \( P = 0.001 \)), and Pitt bacteremia scores of \( \geq 4 \) (23.7% versus 9.5%; \( P < 0.001 \)). The IV group was also more likely to have hospital-acquired infections (22.7% versus 8.8%; \( P < 0.001 \)) and multidrug-resistant pathogens (45.4% versus 22.6%; \( P < 0.001 \)).
Hospitalized patients with Gram-negative bloodstream infection at King Chulalongkorn Memorial Hospital, Thailand during August 1, 2015 to July 31, 2020 were identified based on the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) diagnostic codes. 

n = 2,365

1,348 Excluded
- 126 unavailable medical record data
- 39 discharged or died in the first 24 hours
- 212 needed prolonged antibiotics or chronic infection
- 118 uncontrolled source of infection
- 377 non-general medical ward admission
- 181 negative blood culture
- 202 unavailable oral antibiotic agent susceptibility result
- 10 contraindication to oral route of administration
- 83 refusal of treatment or patients with palliative care with no antibiotic escalation

Patients treated with intravenous antibiotic route.  

n = 451

41 Loss to follow-up on day 30 after discharge

Patients treated with intravenous antibiotic route.  

n = 410

Patients treated with IV to oral antibiotic route transition.  

n = 545

21 Loss to follow-up on day 30 after discharge

Fig 1. Flow diagram for patient selection.  

https://doi.org/10.1371/journal.pone.0273369.g001
| Characteristics                                      | Total (n = 955) | IV group (n = 410) | IV to PO group (n = 545) | P-value |
|------------------------------------------------------|----------------|-------------------|--------------------------|---------|
| Female, n (%)                                        | 547 (57.3)     | 249 (60.7)        | 298 (54.7)               | 0.061   |
| Age, median (IQR) year                               | 71 (60–81)     | 73 (60–82)        | 70 (60–81)               | 0.015   |
| Age ≥ 65 years, n (%)                                | 637 (66.7)     | 274 (66.8)        | 363 (66.6)               | 0.942   |
| **Comorbiditiesa, n (%)**                            |               |                   |                          |         |
| Hypertension                                         | 579 (60.6)     | 251 (61.2)        | 328 (60.2)               | 0.746   |
| Diabetes mellitus                                    | 377 (39.5)     | 161 (39.3)        | 216 (39.6)               | 0.909   |
| Dyslipidemia                                         | 371 (38.8)     | 159 (38.8)        | 212 (38.9)               | 0.970   |
| Cardiovascular disease                               | 258 (27.0)     | 118 (28.8)        | 140 (25.7)               | 0.287   |
| Solid cancer                                         | 242 (25.3)     | 96 (23.4)         | 146 (26.8)               | 0.235   |
| Metastatic solid cancer                              | 97 (40.1)      | 39 (40.6)         | 58 (39.7)                | 0.889   |
| Neurologic disease                                   | 239 (25.0)     | 108 (26.3)        | 131 (24.0)               | 0.416   |
| Chronic kidney disease                               | 162 (17.0)     | 71 (17.3)         | 91 (16.7)                | 0.801   |
| Liver disease                                        | 151 (15.8)     | 67 (16.3)         | 84 (15.4)                | 0.697   |
| Immunologic/Rheumatologic disease                   | 93 (9.7)       | 53 (12.9)         | 40 (7.3)                 | 0.004   |
| Hematologic malignancy                               | 84 (8.8)       | 36 (8.8)          | 48 (8.8)                 | 0.988   |
| End Stage Renal Disease                              | 75 (7.9)       | 45 (11.0)         | 30 (5.5)                 | 0.002   |
| Chronic lung disease                                 | 62 (6.5)       | 23 (5.6)          | 39 (7.2)                 | 0.337   |
| HIV infection (any CD4)                              | 18 (1.9)       | 6 (1.5)           | 12 (2.2)                 | 0.406   |
| Immunocompromised hosta, n (%)                       | 259 (27.1)     | 133 (32.4)        | 126 (23.1)               | 0.001   |
| Immunomodulator or steroid within 1 month            | 143 (15.0)     | 86 (21.0)         | 57 (10.5)                | <0.001  |
| Chemotherapy within 6 months                         | 116 (12.1)     | 51 (12.4)         | 65 (11.9)                | 0.810   |
| ANC ≤ 500 cells/mm³                                   | 56 (5.9)       | 23 (5.6)          | 33 (6.1)                 | 0.772   |
| Solid organ transplant                               | 38 (4.0)       | 26 (6.3)          | 12 (2.2)                 | 0.001   |
| HIV infection (CD4 < 200 cells/mm³)                  | 8 (0.8)        | 2 (0.5)           | 6 (1.1)                  | 0.478b  |
| HCT within 12 months                                 | 3 (0.3)        | 0 (0.0)           | 3 (0.6)                  | 0.264b  |
| qSOFA ≥ score 2, n (%)                               | 303 (31.7)     | 154 (37.6)        | 149 (27.3)               | 0.001   |
| Pitt bacteremia score ≥ 4, n (%)                     | 149 (15.6)     | 97 (23.7)         | 52 (9.5)                 | <0.001  |
| Charlson comorbidity index score ≥ 7, n (%)          | 282 (29.5)     | 120 (29.3)        | 162 (29.7)               | 0.878   |
| Acute kidney injury, n (%)                           | 402 (42.1)     | 199 (48.5)        | 203 (37.2)               | <0.001  |
| Lactate, median (IQR) mmol/L                         | 2.3 (1.4–3.9)  | 2.3 (1.4–4.6)     | 2.2 (1.4–3.7)            | 0.537   |
| WBC at admission, median (IQR) x10³ cells/mm³        | 13.8 (9.3–18.4)| 13.4 (8.80–18.4)  | 14.1 (9.9–18.4)          | 0.198   |
| Received inotropic agents, n (%)                     | 173 (18.1)     | 87 (21.2)         | 86 (15.8)                | 0.031   |
| Septic shock, n (%)                                  | 172 (18.0)     | 86 (21.0)         | 86 (15.8)                | 0.039   |
| ICU admission, n (%)                                 | 98 (10.3)      | 72 (17.6)         | 26 (4.8)                 | <0.001  |
| Length of ICU stay, median (IQR) day                 | 4 (2.0–6.0)    | 4 (2.3–6.0)       | 3 (1.8–5.0)              | 0.274   |
| Mechanical Ventilator required, n (%)                | 123 (12.9)     | 76 (18.5)         | 47 (8.6)                 | <0.001  |
| Hospital acquired infection, n (%)                   | 141 (14.8)     | 93 (22.7)         | 48 (8.8)                 | <0.001  |
| Polymicrobial Gram-negative BSI, n (%)               | 45 (4.7)       | 25 (6.1)          | 20 (3.7)                 | 0.080   |
| Multidrug-resistant pathogens, n (%)                 | 309 (32.4)     | 186 (45.4)        | 123 (22.6)               | <0.001  |
| Source of infection                                  |               |                   |                          |         |
| Primary BSI                                          | 211 (22.1)     | 101 (24.6)        | 110 (20.2)               | 0.101   |
| Urinary tract                                        | 371 (38.8)     | 145 (35.4)        | 226 (41.5)               | 0.055   |
| Intra-abdominal                                      | 248 (26.0)     | 90 (22.0)         | 158 (29.0)               | 0.014   |
| Respiratory tract                                    | 59 (6.2)       | 23 (5.6)          | 36 (6.6)                 | 0.527   |
| Catheter-related                                    | 44 (4.6)       | 34 (8.3)          | 10 (1.8)                 | <0.001  |

(Continued)
The main source of infection was urinary tract (38.8%), followed by intra-abdominal (26%) and primary BSI (22.1%). In the overall cohort, the most common microorganism was *Escherichia coli* (59.2%), followed by *Klebsiella pneumoniae* (15.8%). There was no difference in the frequency of multidrug-resistant *Escherichia coli* between the two study groups (78.5% versus 83.7%; P = 0.254). However, more patients with ceftriaxone-resistant *Escherichia coli* were present in the IV group (82.9% versus 71.8%; P = 0.043). No patients had carbapenem-resistant *Escherichia coli*. Additional microorganism data are shown in Table 2.

In the total population, treatment success was 94.1%, with no statistically significant difference between the two study groups (93.9% in the IV group versus 94.3% in the IV to oral transition group, P = 0.790) (Table 3). The main reason for treatment failure was infection relapse (3.5%). In-hospital mortality occurred in 0.9%. The IV to oral transition group had a significantly shorter median LOS than the IV group (7 days; IQR 5–9 days versus 15 days; IQR 10–24 days, P < 0.001). Six hundred fifty-seven patients (68.8%) had a follow-up blood culture after 72 hours of active antibiotic treatment. Sixteen patients (2.4%) had persistent GN-BSI. Ceftriaxone was the most common empiric therapy, followed by meropenem (47.2% and 21%, respectively).

Based on twelve covariates, one-to-one propensity score matching yielded 594 patients, with 297 patients each in the IV group and the IV to oral transition group, each with the closest propensity scores. Patients’ baseline characteristics after propensity score analysis are shown in the S1 Table. The absolute standardized difference in all baseline covariates before and after propensity score matching was ≤ 0.1 (S1 Fig).

There were notable imbalances in baseline characteristics between the two study groups before the propensity score matching. After the propensity score matching model was used, there was no statistically significant difference in treatment success in the two study groups (95.3% in the IV group versus 92.9% in the IV to oral group, P = 0.223). The IV to oral transition group had a shorter median hospital LOS than the IV group. A comparison of the treatment outcomes between the full cohort and propensity score-matched cohort are shown in Table 3.

In the IV to oral transition group, the most common type of IV to oral transition was step-down therapy (60%), followed by switch therapy (29.5%) and sequential therapy (10.5%). Ciprofloxacin was the most frequently prescribed oral antibiotic agent (53%), followed by cefixime (21%) and amoxicillin/clavulanic acid (10.3%) (Fig 2). Most oral antibiotic agents were classified as having moderate bioavailability (356 patients; 65.3%), followed by low bioavailability (171 patients; 31.4%), and high bioavailability (18 patients; 3.3%).

The median duration of oral antibiotics was eight days (IQR 7–10 days). The median time to defervescence before IV to oral antibiotic transitions was three days (IQR 1–4 days). The median body temperature and WBC were 37.0˚C (IQR 36.7–37.3˚C) and 7,900 cells/mm$^3$ (IQR 5,700–10,600 cells/mm$^3$) on the day of transition to oral antibiotics (S2 Table).
The results of the multivariate analysis evaluating predictors of treatment failure in the IV to oral transition group are shown in Table 4; Independent predictors of treatment failure included metastatic solid cancer (aOR = 4.355, 95% CI 1.727–10.979), HIV infection with a CD4 count < 200 cells/mm$^3$ (aOR = 8.452, 95% CI 1.150–62.114), qSOFA score of ≥ 2 (aOR = 2.545, 95% CI 1.145–5.658), multidrug-resistant pathogen (aOR = 2.849, 95% CI 1.213–6.693), and respiratory tract infection (aOR = 8.447, 95% CI 3.195–22.331). Independent predictors of treatment failure in the overall cohort included metastatic solid cancer (aOR = 3.484, 95% CI 1.649–7.361), HIV infection with CD4 count < 200 cells/mm$^3$ (aOR = 7.359, 95% CI 1.277–42.404), qSOFA score of ≥ 2 (aOR = 2.162, 95% CI 1.217–3.843), CCI score of ≥ 7 (aOR = 2.064, 95% CI 1.056–4.034), polymicrobial GN-BSI (aOR = 2.782,

| Microorganism (n = number of isolates) | Total (1,004 isolates) | IV group (438 isolates) | IV to PO group (566 isolates) | P-value |
|----------------------------------------|------------------------|-------------------------|-------------------------------|---------|
| Enterobacterales, n (%)                | 847 (84.4)             | 373 (85.2)              | 474 (83.7)                    | 0.541   |
| *Escherichia coli*                     | 594 (70.1)             | 254 (68.1)              | 340 (71.7)                    | 0.251   |
| *Klebsiella pneumoniae*                | 159 (18.8)             | 79 (21.2)               | 80 (16.9)                     | 0.111   |
| *Proteus mirabilis*                    | 30 (3.5)               | 13 (3.5)                | 17 (3.6)                      | 0.937   |
| Enterobacter spp.                      | 22 (2.6)               | 10 (2.7)                | 12 (2.5)                      | 0.892   |
| *Citrobacter spp.*                     | 9 (1.1)                | 4 (1.1)                 | 5 (1.1)                       | 1.000   |
| *Klebsiella oxytoca*                   | 9 (1.1)                | 0 (0)                   | 9 (1.9)                       | 0.006*  |
| *Morganella morganii*                  | 9 (1.1)                | 5 (1.3)                 | 4 (0.8)                       | 0.518*  |
| *Serratia marcescens*                  | 5 (0.6)                | 4 (1.1)                 | 1 (0.2)                       | 0.175*  |
| Others$^b$                              | 10 (1.2)               | 4 (1.1)                 | 6 (1.3)                       | 1.000*  |
| Non-lactose fermenter, n (%)           | 92 (9.2)               | 46 (10.5)               | 46 (8.1)                      | 0.196   |
| *Pseudomonas aeruginosa*               | 45 (48.9)              | 19 (41.3)               | 26 (56.5)                     | 0.144   |
| *Acinetobacter baumannii*              | 21 (22.8)              | 13 (28.3)               | 8 (17.4)                      | 0.214   |
| *Acinetobacter spp.*                   | 11 (12.0)              | 5 (10.9)                | 6 (13.0)                      | 0.748   |
| *Stenotrophomonas maltophilia*         | 7 (7.6)                | 3 (6.5)                 | 4 (8.7)                       | 1.000   |
| *Burkholderia cepacia*                 | 5 (5.4)                | 5 (10.9)                | 0 (0)                         | 0.056*  |
| *Pseudomonas stutzeri*                 | 3 (3.3)                | 1 (2.2)                 | 2 (4.3)                       | 1.000   |
| *Acronomas spp., n (%)                 | 39 (3.9)               | 9 (2.1)                 | 30 (5.3)                      | 0.008   |
| *Vibrio cholerae, n (%)                | 11 (1.1)               | 3 (0.7)                 | 8 (1.4)                       | 0.365   |
| *Hemophilus influenzae, n (%)          | 6 (0.7)                | 1 (0.2)                 | 5 (0.9)                       | 0.240   |
| Others$^c$, n (%)                       | 9 (0.9)                | 6 (1.4)                 | 3 (0.5)                       | 0.189   |

| Multidrug-resistant pathogens; total 309 isolates, n (%) |
|----------------------------------------------------------|
| *MDR-Escherichia coli*                                   | 249 (80.6)             | 146 (78.5)              | 103 (83.7)                    | 0.254   |
| *CEF-resistant E. coli*                                  | 195 (78.3)             | 121 (82.9)              | 74 (71.8)                     | 0.043   |
| *MDR-Klebsiella pneumoniae*                              | 36 (11.7)              | 27 (14.5)               | 9 (7.3)                       | 0.054   |
| *MDR-Enterobacter spp.*                                  | 4 (1.3)                | 0 (0)                   | 4 (3.3)                       | 0.029*  |
| *MDR-Acinetobacter baumannii*                            | 4 (1.3)                | 3 (1.6)                 | 1 (0.8)                       | 1.000   |

Notes
$^a$Fisher’s exact test.
$^b$Other Enterobacterales: *Edwardsiella tarda* (3), *Salmonella enterica* (3), *Providencia stuartii* (2), *Plesiomonas shigelloides* (1), *Escherichia fergusonii* (1).
$^c$Other microorganisms: *Moraxella spp.* (4), *Ralstonia spp.* (2), *Rhizobium radiobacter* (1), *Shewanella putrefaciens* (1), *Sphingomonas paucimobilis* (1).

Abbreviations: IV, intravenous administration; PO, oral administration; MDR, multidrug-resistant; *E. coli*, *Escherichia coli*.

https://doi.org/10.1371/journal.pone.0273369.t002

The results of the multivariate analysis evaluating predictors of treatment failure in the IV to oral transition group are shown in Table 4; Independent predictors of treatment failure included metastatic solid cancer (aOR = 4.355, 95% CI 1.727–10.979), HIV infection with a CD4 count < 200 cells/mm$^3$ (aOR = 8.452, 95% CI 1.150–62.114), qSOFA score of ≥ 2 (aOR = 2.545, 95% CI 1.145–5.658), multidrug-resistant pathogen (aOR = 2.849, 95% CI 1.213–6.693), and respiratory tract infection (aOR = 8.447, 95% CI 3.195–22.331). Independent predictors of treatment failure in the overall cohort included metastatic solid cancer (aOR = 3.484, 95% CI 1.649–7.361), HIV infection with CD4 count < 200 cells/mm$^3$ (aOR = 7.359, 95% CI 1.277–42.404), qSOFA score of ≥ 2 (aOR = 2.162, 95% CI 1.217–3.843), CCI score of ≥ 7 (aOR = 2.064, 95% CI 1.056–4.034), polymicrobial GN-BSI (aOR = 2.782,
Table 3. Treatment and outcomes of hospitalized patients with Gram-negative bloodstream infection treated with intravenous antibiotic agents or receiving intravenous to oral transition antibiotics (n = 955), and after propensity score matched cohort (n = 594).

| Characteristics                              | Full cohort (n = 955) | Propensity score matching (n = 594) |
|----------------------------------------------|-----------------------|-----------------------------------|
|                                              | Total (n = 955) | IV group (n = 410) | IV to PO group (n = 545) | P-value | IV group (n = 297) | IV to PO group (n = 297) | P-value |
| Treatment success, n (%)                     | 899 (94.1)  | 385 (93.9)  | 514 (94.3)  | 0.790  | 283 (95.3)  | 276 (92.9)  | 0.223  |
| Treatment failure, n (%)                     | 56 (5.9)    | 25 (6.1)    | 31 (5.7)    | 0.790  | 14 (4.7)    | 21 (7.1)    | 0.223  |
| Relapsed infection within 30 days            | 33 (3.5)    | 17 (4.1)    | 16 (2.9)    | 9 (3.0) | 11 (3.7)    | 9 (3.0)     | 11 (3.7) |
| PO to IV transition                          | 15 (1.6)    | 0 (0)       | 15 (2.8)    | 0 (0)  | 10 (3.4)    | 10 (3.4)    | 0.223  |
| In-hospital mortality                        | 9 (0.9)     | 8 (2.0)     | 1 (0.2)     | 5 (1.7) | 1 (0.3)     | 1 (0.3)     | 0.223  |
| Relapsed infection within 14 days, n (%)     | 21 (2.2)    | 10 (2.4)    | 11 (2.0)    | 0.661  | 7 (2.4)     | 8 (2.7)     | 0.794  |
| Duration of antibiotic therapy, median (IQR) day | 14 (14–14) | 14 (13–14) | 14 (14–14) | 0.269  | 14 (12–14) | 14 (14–14) | 0.001  |
| Duration of IV antibiotic therapy, median (IQR) day | 8 (5–14)    | 14 (13–14) | 6 (4–7)     | <0.001 | 14 (11–14) | 6 (4–17)    | <0.001 |
| Length of stay, median (IQR) day             | 9 (6–15)    | 15 (10–24)  | 7 (5–9)     | <0.001 | 14 (9–21)  | 7 (5–10)    | <0.001 |
| Inactive empirical antibiotic therapy, n (%) | 148 (15.5)  | 84 (20.5)   | 64 (11.7)   | <0.001 | 64 (21.5)  | 58 (19.5)   | 0.052  |
| Time to appropriate antibiotic therapy, median (IQR) day | 1 (1–1) | 1 (1–1) | 1 (1–1) | <0.001 | 1 (1–1) | 1 (1–1) | 0.400  |
| Persistent GN-BSI, n (%)                     | 16 (2.4)    | 10 (2.7)    | 6 (2.1)     | 0.666  | 5 (1.9)     | 5 (2.9)     | 0.470  |

Empirical therapy, n (%)

| Ceftriaxone                                   | 451 (47.2) | 140 (34.1) | 311 (57.1) | <0.001 | 125 (42.1) | 136 (45.8) | 0.363  |
| Meropenem                                     | 201 (21.0) | 66 (16.1)  | 74 (13.6)  | <0.001 | 70 (23.6)  | 57 (19.2)  | 0.173  |
| Ceftazidime                                   | 155 (16.2) | 66 (16.1)  | 89 (16.3)  | 0.923  | 53 (17.8)  | 54 (18.2)  | 0.915  |
| Piperacillin/tazobactam                       | 101 (10.6) | 55 (13.4)  | 46 (8.4)   | 0.013  | 37 (12.5)  | 36 (12.1)  | 0.901  |
| Imipenem                                      | 22 (2.3)   | 11 (2.7)   | 11 (2.0)   | 0.498  | 4 (1.3)    | 7 (2.4)    | 0.361  |
| Ciprofloxacin                                 | 14 (1.5)   | 4 (1.0)    | 10 (1.8)   | 0.274  | 3 (1.0)    | 4 (1.3)    | 1.000b |
| Levofloxacin                                  | 6 (0.6)    | 5 (1.2)    | 1 (0.2)    | 0.090b | 2 (0.7)    | 1 (0.3)    | 1.000b |
| Ertapenem                                     | 3 (0.3)    | 2 (0.5)    | 1 (0.2)    | 0.580b | 2 (0.7)    | 1 (0.3)    | 1.000b |
| Amoxicillin/clavulanic acid                   | 2 (0.2)    | 1 (0.2)    | 1 (0.2)    | 1.000b | 1 (0.3)    | 1 (0.3)    | 1.000b |
| Combination therapy with other antibiotics, n (%) | 67 (7.0) | 45 (11.0) | 22 (4.0) | <0.001 | 32 (10.8) | 9 (3.0) | <0.001 |
| Vancomycin                                    | 41 (4.3)   | 31 (7.6)   | 10 (1.8)   | <0.001 | 21 (7.1)   | 7 (2.4)    | 0.007  |
| Colistin                                      | 7 (0.7)    | 7 (1.7)    | 0 (0)      | 0.003b | 3 (1.0)    | 0 (0)      | 0.249b |
| Fosfomycin                                    | 2 (0.2)    | 1 (0.2)    | 1 (0.2)    | 1.000b | 0 (0)      | 0 (0)      | 0.000   |
| Antibiotic de-escalation, n (%)               | 336 (35.2) | 161 (39.3) | 175 (32.1) | 0.022  | 103 (34.7) | 124 (41.8) | 0.076  |
| Antibiotic escalation, n (%)                  | 147 (15.4) | 99 (24.1)  | 48 (8.8)   | <0.001 | 79 (26.6)  | 36 (12.1)  | <0.001 |

Notes: *Multiple reports possible
bFisher’s exact test, de-escalation: Narrower spectrum of antibiotics, escalation: Broader spectrum of antibiotics.

Abbreviations: IV, intravenous administration; PO, oral administration; IQR, interquartile range; GN-BSI, Gram-negative bloodstream infection.

Discussion

The study found a high frequency of treatment success in patients with GN-BSI who received IV to oral transition. There was no significant difference in the treatment success between 95% CI 1.091–7.095), multidrug-resistant pathogen (aOR = 2.421, 95% CI 1.362–4.305), and respiratory tract infection (aOR = 3.932, 95% CI 1.761–8.782) (S3 Table). Independent predictors of treatment failure in the IV group included metastatic solid cancer (aOR = 3.809, 95% CI 1.186–12.238), immunocompromised hosts (aOR = 3.319, 95% CI 1.262–8.734), and qSOFA score of ≥ 2 (aOR = 2.807, 95% CI 1.076–7.326) (S4 Table).
continuing IV antibiotic agents versus IV to oral transition in multivariate analysis in the overall cohort and our analysis with propensity score matching. This finding mirrors two previous randomized controlled trials by Amodio-Groton M et al. in bacteremic patients treated with ciprofloxacin [28] and Park TY et al. in patients who were bacteremic secondary to acute cholangitis [29]. As expected in a non-randomized study where a choice of therapy will be determined by patient clinical status, and consistent with previous findings, the group that did not undergo PO transition in our study had patients that were more immunocompromised, more severely ill, and had more hospital-acquired infections and multidrug-resistant pathogens [6,8]. Further studies are needed to support using the IV to oral transition in these groups of patients. Patients in our study’s IV to oral transition group had a shorter hospital LOS, similar to many previous studies [6–8,28]. This may have direct and indirect cost-benefit to patients and the healthcare system. Based on our results, patients with improved clinical response (afebrile and normal white blood cell count) for at least three days may be considered for IV to oral transitions. The median duration of IV antibiotic agents was six days, similar to a retrospective cohort study by Rieger KL et al. [8] and Nisly SA et al. [30]. Of note, a survey study by Thaden JT et al. [31] found most infectious disease specialists recommend extended ≥ 5 days of IV therapy before oral step-down antibiotics. The total duration of antibiotic therapy was 14 days in patients with IV to oral transition group in our study. The survey by Hospenthal DR et al. of infectious disease physician practices regarding transitioning from IV to oral therapy in patients with GN-BSI showed that 46% of responders preferred the total duration of total therapy to 14 days [32]. A systematic review and meta-analysis showed that shorter durations

**Notes:** Others: Cefditoren (2), Amoxicillin (1), Cefuroxime (1), Cephalexin (1)

Fig 2. Oral antibiotic agents used in patients in the intravenous to oral antibiotic transition group (n = 545).

https://doi.org/10.1371/journal.pone.0273369.g002
of antibiotic therapy in uncomplicated GN-BSI resulted in good outcomes [33]. Patients’ baseline characteristics from two randomized controlled trials were similar to our study. Most patients in the trials were less severely ill with source control, and the urinary tract was the primary source of infection [34,35]. That might explain the high treatment success in our study. Future studies are

Table 4. Factors associated with treatment failure in hospitalized patients with Gram-negative bloodstream infection in intravenous to the oral antibiotic agent transition group (n = 545).

| Factors | Univariate analysis¹ | Multivariate analysis² |
|---------|----------------------|------------------------|
|         | OR                   | 95% CI                  | P-value | aOR | 95% CI | P-value |
| Age ≥ 65 years | 1.471               | 0.645–3.357            | 0.359    |
| Diabetes mellitus | 1.272               | 0.613–2.637            | 0.518    |
| Chronic kidney disease | 0.519               | 0.154–1.744            | 0.289    |
| Cardiovascular disease | 1.905               | 0.900–4.031            | 0.092    |
| Hematologic malignancy | 1.582               | 0.530–4.728            | 0.411    |
| Solid cancer | 2.069               | 0.987–4.337            | 0.054    |
| Metastatic solid cancer | 3.288               | 1.372–7.596            | 0.007    |
| HIV infection (any CD₄⁺) | 3.476               | 0.728–16.601           | 0.118    |
| HIV infection (CD₄ < 200 cells/mm³) | 8.793               | 1.546–50.004           | 0.014    |
| ANC < 500 cells/mm³ | 1.729               | 0.497–6.012            | 0.389    |
| Hospital acquired infection | 2.106               | 0.770–5.765            | 0.147    |
| qSOFA score ≥ 2 | 2.312               | 1.110–4.817            | 0.025    |
| Pitt bacteremia score ≥ 4 | 2.442               | 0.953–6.258            | 0.063    |
| CCI score ≥ 7 | 2.689               | 1.296–5.579            | 0.008    |
| Mechanical ventilator required | 2.157               | 0.787–5.908            | 0.135    |
| Received inotropic agents | 1.028               | 0.383–2.756            | 0.956    |
| Septic shock | 1.028               | 0.383–2.756            | 0.956    |
| ICU admission | 0.652               | 0.085–4.977            | 0.680    |
| Polymicrobial GN-BSI | 3.335               | 0.917–12.121           | 0.067    |
| Multidrug-resistant pathogen | 2.653               | 1.261–5.581           | 0.010    |
| *Escherichia coli* | 0.839               | 0.402–1.751            | 0.641    |
| *Klebsiella pneumoniae* | 2.135               | 0.920–4.957            | 0.077    |
| *MDR- Klebsiella pneumoniae* | 4.955               | 0.993–25.125           | 0.051    |
| *Pseudomonas aeruginosa* | 0.652               | 0.085–4.977            | 0.680    |
| Intra-abdominal infection | 0.572               | 0.230–1.421            | 0.229    |
| Urinary tract infection | 0.885               | 0.421–1.863            | 0.748    |
| Respiratory tract infection | 6.037               | 2.479–14.703           | <0.001   |
| Indwelling foley catheter | 1.913               | 0.925–3.958            | 0.080    |
| Inactive empirical antibiotic therapy | 1.121               | 0.379–3.314            | 0.836    |
| Moderate to high bioavailability | 0.615               | 0.294–1.285            | 0.196    |
| Low bioavailability | 1.627               | 0.778–3.402            | 0.196    |
| Oral cephalosporins | 1.642               | 0.785–4.343            | 0.187    |
| Oral fluoroquinolones | 0.437               | 0.225–0.994            | 0.488    |
| Oral trimethoprim/sulfamethoxazole | 1.870               | 0.229–15.252           | 0.559    |
| Oral amoxicillin/clavulanate | 1.746               | 0.642–4.745            | 0.275    |

Notes: ¹Univariate analysis by Enter method ²Multivariate analysis by Backward LR stepwise.

Abbreviations: OR, Odds ratio; 95% CI, 95% confidence interval; aOR, adjusted odds ratio; NS, Non-statistically significant; HIV, Human Immunodeficiency Virus; mm³, cubic millimeter; ANC, absolute neutrophil count; qSOFA, quick Sepsis-related Organ Failure Assessment; CCI, Charlson comorbidity index; ICU, intensive care unit; GN-BSI, Gram-negative bloodstream infection; MDR, multidrug-resistant.

https://doi.org/10.1371/journal.pone.0273369.t004
required to inform the optimal duration of treatment in patients with GN-BSI who transition from IV to oral therapy, both complicated and uncomplicated bacteremia.

The treatment failure in our study was low at 5.9%, similar to a cohort study by Rieger KL et al. [8]. However, our treatment failure was higher than a study by Thurber KM et al. [7]. They found treatment failure occurred in 2.4% in their IV group and 1.5% in their IV to oral transition group. Their study included less severe patients with GN-BSI, all of which had urinary tract sources. Our study also observed higher in-hospital mortality in the IV group, likely due to the higher severity of illness at baseline. The same trends as the study of Rieger KL et al. [8]. Our study excluded patients admitted to the non-general medical ward of 377 patients (15.9%). The non-medical general ward consisted of ICU, trauma/burn unit, orthopedic ward, and surgical ward. The main reasons we excluded the non-medical general ward were an uncontrolled source of infection followed by a need to prolong the use of antibiotics, which are essential confounders and impact our treatment outcome. We can’t generalize our result to this group of patients. The in-hospital mortality in our study was lower than in the previous study, although some patients had infections outside urinary tract sources and in the critical illness at admission [8]. This may be partly because all patients in our study had a controlled source of infection, didn’t have chronic conditions, or needed prolonged use of antibiotics.

To date, limited studies have assessed predictors of treatment failure in patients who underwent IV to oral antibiotic transition in GN-BSI. A retrospective cohort study was conducted in the USA by Kutob LF et al. to identify factors associated with treatment failure in GN-BSI patients with IV to oral transition [36]. They found four independent risk factors for treatment failure, including an immunocompromised host (adjusted hazard ratio (aHR) = 4.62), liver cirrhosis (aHR = 7.77), and patients who received a moderate (aHR = 5.94) or low bioavailability antibiotic (aHR = 7.67). Unlike previous studies, we evaluated factors associated with treatment failure in both continuing IV and IV to oral transition groups. Metastatic solid cancer and qSOFA score of ≥ 2 were associated with treatment failure in both groups; therefore, regardless of approach, these populations are more likely to have treatment failure. However, we found the IV to oral transition group had unique predictors of treatment failure that were not found in the IV group. These independent predictors of treatment failure included patients with HIV infection with CD4 < 200 cells/mm³, MDR pathogen, or respiratory tract infection. To our knowledge, no previous studies have found these three factors to be predictive of treatment failure in patients undergoing IV to oral transition. Further research is required in these patient populations. Factors associated with treatment failure in the full cohort were similar to the IV to oral transition group. In our study, more than 50% of patients were in the IV to oral transition group. The oral antibiotics used in our study differed from previous reports, given that cefixime was our second most frequently used agent [6,7,30,36,37]. Low penetration of oral third-generation cephalosporins to the epithelial lining fluid may partly explain our finding that respiratory tract infection was an independent predictor of treatment failure [38].

There was no difference in treatment failure based on the bioavailability classification of the oral agent. That is in contrast with a retrospective cohort study by Kutob LF et al., which found that treatment failure occurred in 2%, 12%, and 14% in patients receiving oral antibiotics with high, moderate, and low bioavailability, respectively (P = 0.02) [36]. Our study is the largest study to evaluate factors associated with treatment failure in IV to oral antibiotic transition in GN-BSI. Due to the low frequency of treatment failure in the IV to oral group, we may be underpowered to determine any impact of bioavailability on treatment failure.

Bioavailability is not the only factor associated with treatment success in GN-BSI. Antibiotic penetration at the site and pharmacodynamics, infection source, and patient’s gastrointestinal absorption will also impact treatment success. All patients in our study had an intact gastrointestinal function and received infectious source control. The main source of infection
was urinary tract, which mirrors study by Nisly SA et al., comparing oral fluoroquinolones versus oral Beta-lactams versus oral trimethoprim/sulfamethoxazole in GN-BSIs and Mercuro NJ et al., comparing oral fluoroquinolones versus oral Beta-lactams in Enterobacterales BSI [30,37]. These factors also likely contributed to the lack of association of bioavailability to treatment success in our study. Moderate bioavailability agents were the most commonly prescribed in our study, similar to five previous cohort studies [6–7,30,36,37]. And ciprofloxacin was our study’s most frequently used oral agent, which is also consistent with prior studies [6–8,30,36,37]. A once-daily dose of antibiotics can improve a patient’s compliance. Levofloxacin and moxifloxacin are categorized as being highly bioavailable and also once-daily dose. Thailand is an endemic tuberculosis area, and we preserve levofloxacin and moxifloxacin for Multi-drug-resistant or Extensively drug-resistant tuberculosis treatment. Ciprofloxacin was the most common oral antibiotic prescribed, followed by cefixime and amoxicillin/clavulanic acid. These three antibiotics are listed in Thailand’s national essential drug list (NELM) [39]. Thai hospitals encourage physicians to use medications in the NELM given their cost-effectiveness and universal coverage for all patients. Outpatient parenteral antimicrobial therapy (OPAT) programs can shorten LOS and improve cost-effectiveness [40]. However, OPAT is not practical for most patients at our hospital. Some patients cannot afford it or are unable to be connected with outpatient care providers to facilitate drug distribution and home nursing due to mobility issues. IV to oral transition in GN-BSI is more suitable than OPAT for our patients.

There are some strengths and limitations to our study. To our knowledge, this is the first study to evaluate the treatment success in both IV and IV to oral transition antibiotics in GN-BSI for all infection sources and microorganisms. This can reflect real-life clinical practice. Our study also identified risk factors associated with treatment failure in the IV and IV to oral transition groups. Most previous studies included only patients with Enterobacterales BSI, primarily from a urinary source. Another strength of our study, the clinical pharmacist in the medical ward advised and counseled all hospitalized patients about their discharge antibiotic therapy to improve patient adherence. We also assessed oral agents with low bioavailability, which is often not evaluated in other studies. For limitations, first, although we included a broad population of patients with GN-BSI, only a minority of patients were infected with non-lactose-fermenting Gram-negatives; thus, we cannot make general conclusions about those patients. Second, our study had fewer patients with immunocompromised status; therefore, we cannot apply our results to these specific groups of patients. Third, our study evaluated in-hospital mortality, a short-term outcome that does not capture mortality that may occur at later time points. However, our study followed-up patients for relapsed infection within 30 days after treatment completion; we might see the data for mortality during that period. Fourth, Controlling the confounding is the limitation in retrospective studies. Lastly, there were 62 patients lost to follow-up on day 30 after hospital discharge due to the inherent limitation of retrospective studies.

**Conclusion**

We suggest intravenous to oral antibiotic transition be considered in patients with GN-BSIs who are hemodynamically stable with a functioning gastrointestinal tract and have source control. Careful consideration should be given to patients with HIV infection with CD4 count < 200 cells/mm3, those infected with MDR pathogens, or those with a respiratory source of infection, given these were risk factors for treatment failure. Transitioning from intravenous to oral antibiotic agents has many benefits. Still, limited data about the appropriate duration of therapy for both intravenous and oral therapy, and treatment in patient subpopulations, require additional research.
Supporting information

S1 Fig. Absolute standardized difference in all baseline covariates before and after propensity score matching.
(TIF)

S1 Table. Baseline characteristics of hospitalized patients with Gram-negative bloodstream infection continuing intravenous antibiotic agents or receiving intravenous to oral transition antibiotics in the full cohort (n = 955) and after propensity score matching model (n = 594).
(DOCX)

S2 Table. Clinical data of hospitalized patients with Gram-negative bloodstream infection in intravenous to oral antibiotic agent transitions (n = 545).
(DOCX)

S3 Table. Factors associated with treatment failure in hospitalized patients with Gram-negative bloodstream infection continuing intravenous antibiotic agents or receiving intravenous to oral transition antibiotics (n = 955).
(DOCX)

S4 Table. Factors associated with treatment failure in hospitalized patients with Gram-negative bloodstream infection continuing intravenous antibiotic agent group (n = 410).
(DOCX)

Acknowledgments

The author(s) would like to thank King Chulalongkorn Memorial Hospital’s staff for their data collection cooperation, and we would like to thank Mrs. Jiratchaya Sophonphan and Mr. Bovornpat Suriyapakorn for the statistic consultation.

Ethics approval

This study was ethically approved by the Institutional Review Board of the Faculty of Medicine at Chulalongkorn University (IRB No.744/63). All data were fully anonymized before we accessed them, and the IRB waived the requirement for informed consent.

Author Contributions

Conceptualization: Titawadee Pradubkham, Gompol Suwanpimolkul, Alan Edward Gross, Chotirat Nakaranurack.

Data curation: Titawadee Pradubkham.

Formal analysis: Titawadee Pradubkham, Chotirat Nakaranurack.

Writing – original draft: Titawadee Pradubkham.

Writing – review & editing: Titawadee Pradubkham, Gompol Suwanpimolkul, Alan Edward Gross, Chotirat Nakaranurack.

References

1. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect. 2013 Jun; 19(6):501–9. https://doi.org/10.1111/1469-0691.12195 PMID: 23473333
2. Buetti N, Atkinson A, Marschall J, Kronenberg A; Swiss Centre for Antibiotic Resistance (ANRESIS). Incidence of bloodstream infections: a nationwide surveillance of acute care hospitals in Switzerland 2008–2014. BMJ Open. 2017 Mar 21; 7(3):e013665.

3. Landesman SH, Gorbach SL. Gram-negative sepsis and shock. Orthop Clin North Am. 1978 Jul; 9(3):611–25. PMID: 358039

4. Gikas A, Samonis G, Christidou A, Papadakis J, Koveridis D, Tselentis Y, et al. Gram-negative bacteremia in non-neutropenic patients: a 3-year review. Infection. 1998 May-Jun; 26(3):155–9. https://doi.org/10.1007/BF02771841 PMID: 9646106

5. Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Predictive scoring model of mortality in Gram-negative bloodstream infection. Clin Microbiol Infect. 2013 Oct; 19(10):948–54. https://doi.org/10.1111/cmi.12085 PMID: 23190091

6. Tamma PD, Conley AT, Cosgrove SE, Harris AD, Lautenbach E, Amoah J, et al.; Antibacterial Resistance Leadership Group. Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia. JAMA Intern Med. 2019 Mar 1; 179(3):316–323.

7. Thuber KM, Arnold JR, Narayanan PP, Dierkhising RA, Sampath Kumar P. Comparison of intravenous and oral definitive antibiotic regimens in hospitalised patients with Gram-negative bacteraemia from a urinary tract infection. J Glob Antimicrob Resist. 2019 Sep; 18:243–248. https://doi.org/10.1016/j.jgar.2019.03.013 PMID: 30926468

8. Rieger KL, Bosso JA, MacVane SH, Temple Z, Wahlquist A, Bohm N. Intravenous-only or Intravenous Transited to Oral Antibiotics for Enterobacteriaceae-Associated Bacteremic Urinary Tract Infection. Pharmacotherapy. 2017 Nov; 37(11):1479–1483. https://doi.org/10.1002/phar.2024 PMID: 28866655

9. Suzuki H, Perencievich EN, Nair R, Livorsi DJ, Goto M. Excess Length of Acute Inpatient Stay Attributable to Acquisition of Hospital-Onset Gram-Negative Bloodstream Infection with and without Antibiotic Resistance: A Multistate Model Analysis. Antibiotics (Basel). 2020 Feb 23; 9(2):96. https://doi.org/10.3390/antibiotics9020096 PMID: 32102195

10. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb 12; 399(10325):629–55. https://doi.org/10.1016/S0140-6736(21)02724-0 PMID: 35065702

11. National Antimicrobial Resistant Surveillance Center, Thailand [updated 2021; cited 2022 Apr 14]. Available from http://narst.dmcs.moph.go.th/data/AMR%202000-2020-12M.pdf.

12. Antimicrobial stewardship programmes in healthcare facilities in low-and middle-income countries: a WHO practical toolkit [Internet]. World Health Organization. [updated 2019 Oct 22; cited 2022 Apr 14]. Available from http://www.who.int/publications/i/item/9789241515481.

13. Sevinc F, Prins JM, Koopmans RP, Langendijk PN, Bossuyt PM, Dankert J, et al. Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. J Antimicrob Chemother. 1999 Apr; 43(4):601–6. https://doi.org/10.1093/jac/43.4.601 PMID: 10350396

14. Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek HWPM, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016 Jul; 16(7):847–856. https://doi.org/10.1016/S1473-3099(16)00665-7 PMID: 26947717

15. Laing RB, Mackenzie AR, Shaw H, Gould IM, Douglas JG. The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards. J Antimicrob Chemother. 1998 Jul; 42(1):107–11. https://doi.org/10.1093/jac/42.1.107 PMID: 9700538

16. Banko H, Goldwater SH, Adams E. Smoothing the Path for Intravenous (IV) to Oral (PO) Conversion: Where Have We Come in 11 Years? Hospital Pharmacy. 2009; 44(11):959–967.

17. Clinical and Laboratory Standards Institute. M100 Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2019.

18. 2020 NHSN Patient Safety Component Manual-CDC [Internet]. Center for Disease Control and Prevention [updated 2020 Jan; cited 2020 Mar 16]. Available from https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf.

19. Gerner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988 Jun; 16(8):128–40. https://doi.org/10.1016/0196-6535(88)90053-3 PMID: 2841893

20. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23; 315(8):801–10. https://doi.org/10.1001/jama.2016.0287 PMID: 26903338
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373–83. https://doi.org/10.1016/0021-9681(87)90171-7 PMID: 3558716

22. Hill PC, Birch M, Chambers S, Drinkovic D, Ellis-Pegler RB, Everts R, et al. Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality. Intern Med J. 2001 Mar; 31(2):97–103. PMID: 11480485

23. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents. 1999 Jan; 11(1):7–12. https://doi.org/10.1016/s0924-8579(98)00060-0 PMID: 10075272

24. Hill PC, Birch M, Chambers S, Drinkovic D, Ellis-Pegler RB, Everts R, et al. Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality. Intern Med J. 2001 Mar; 31(2):97–103. PMID: 11480485

25. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar; 18(3):268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x PMID: 21793988

26. Cyriac JM, James E. Switch over from intravenous to oral therapy: A concise overview. J Pharmaco Ther. 2014 Apr; 5(2):83–7. https://doi.org/10.4103/0976-500X.130042 PMID: 24799810

27. Wetzstein GA. Intravenous to oral (iv: po) anti-infective conversion therapy. Cancer Control. 2000 Mar; 7(2):170–6. https://doi.org/10.1177/107327480000700211 PMID: 10783821

28. Amodio-Groton M, Madu A, Madu CN, Briceland LL, Seligman M, McMaster P, et al. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis. Ann Pharmacother. 1996 Jun; 30(6):596–602. https://doi.org/10.1177/106002809603000605 PMID: 8792944

29. Park TY, Choi JS, Song TJ, Do JH, Choi SH, Oh HC. Early oral antibiotic switch compared with conventional intravenous antibiotic therapy for acute cholangitis with bacteremia. Dig Dis Sci. 2014 Nov; 59 (11):2790–8. https://doi.org/10.1007/s10620-014-3233-0 PMID: 24898101

30. Nisly SA, McClain DL, Fillius AG, Davis KA. Oral antibiotics for the treatment of Gram-negative blood-stream infections: A retrospective comparison of three antibiotic classes. J Glob Antimicrob Resist. 2020 Mar; 7(2):74–77. https://doi.org/10.1016/j.jgar.2019.07.026 PMID: 31390537

31. Thaden JT, Tamma PD, Doi Y, Daneman N; Antibacterial Resistance Leadership Group (ARLG). Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections. Int J Antimicrob Agents. 2021 Oct 20.106451.

32. Hospenthal DR, Waters CD, Beekmann SE, Polgreen PM. Practice Patterns of Infectious Diseases Physicians in Transitioning From Intravenous to Oral Therapy in Patients With Bacteremia. Open Forum Infect Dis. 2019 Aug 30; 7(12):ozz386. https://doi.org/10.1093/ofid/ozz386 PMID: 33335941

33. Li X, Liu C, Mao Z, Li Q, Qi S, Zhou F. Short-course versus long-course antibiotic treatment in patients with uncomplicated gram-negative bacteraemia: A systematic review and meta-analysis. J Clin Pharm Ther. 2021 Feb; 46(1):173–80. https://doi.org/10.1111/jcpt.13277 PMID: 32981149

34. von Dach E, Albrich WC, Brunel AS, Prendki V, Cuvelier C, Flury D, et al. Effect of C-Reactive Protein-standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar; 18(3):268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x PMID: 21793988

35. Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al.; Bacteremia Duration Study Group. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Randomized Clinical Trial. JAMA. 2020 Jun 2; 323(1):190–9. https://doi.org/10.1001/jama.2020.6348 PMID: 32484549

36. Park TY, Choi JS, Song TJ, Do JH, Choi SH, Oh HC. Early oral antibiotic switch compared with conventional intravenous antibiotic therapy for acute cholangitis with bacteremia. Dig Dis Sci. 2014 Nov; 59 (11):2790–8. https://doi.org/10.1007/s10620-014-3233-0 PMID: 24898101

37. Rhee JY, Kwon KT, Ki HK, Shin SY, Jung DS, Chung DR, et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock. 2009 Feb; 31(2):146–50. https://doi.org/10.1097/SHK.0b013e318182f98f PMID: 18636041

38. Cook PJ, Andrews JM, Wise R, Honeybourne D. Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments. J Antimicrob Chemother. 1996 Feb; 37(2):331–9. https://doi.org/10.1093/jac/37.2.331 PMID: 8675549

39. Thailand's national essential drug list (NELM) 2021 [Internet]. National Drug Information, Thailand [updated 2021 May 31; cited 2021 Oct 10]. Available from http://ndl.moph.go.th/uploads/file_news/20210723999860392.pdf.
40. Minton J, Murray CC, Meads D, et al. The Community IntraVenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy. Southampton (UK): NIHR Journals Library; 2017 Feb. (Health Services and Delivery Research, No. 5.6.) Chapter 2, Systematic review of the efficacy, safety and cost-effectiveness of outpatient parenteral antimicrobial therapy. Available from: https://www.ncbi.nlm.nih.gov/books/NBK424119/